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ABSTRACT
End-binding 1 protein (EB1) is a key player in the regulation of microtubule 
(MT) dynamics. Here, we investigated the role of EB1 in glioblastoma (GBM) 
tumor progression and its potential predictive role for response to Vinca-alkaloid 
chemotherapy. Immunohistological analysis of the 109 human GBM cases revealed 
that EB1 overexpression correlated with poor outcome including progression-free 
survival and overall survival. Downregulation of EB1 by shRNA inhibited cell migration 
and proliferation in vitro. Conversely, EB1 overexpression promoted them and 
accelerated tumor growth in orthotopically-transplanted nude mice. Furthermore, 
EB1 was largely overexpressed in stem-like GBM6 that display in vivo a higher 
tumorigenicity with a more infiltrative pattern of migration than stem-like GBM9. 
GBM6 showed strong and EB1-dependent migratory potential. The predictive role of 
EB1 in the response of GBM cells to chemotherapy was investigated. Vinflunine and 
vincristine increased survival of EB1-overexpressing U87 bearing mice and were more 
effective to inhibit cell migration and proliferation in EB1-overexpressing clones than 
in controls. Vinca inhibited the increase of MT growth rate and growth length induced 
by EB1 overexpression. Altogether, our results show that EB1 expression level has 
a prognostic value in GBM, and that Vinca-alkaloid chemotherapy could improve the 
treatment of GBM patients with EB1-overexpressing tumor.
INTRODUCTION
End-binding 1 protein (EB1) is an evolutionary 
conserved protein that preferentially localizes to 
the plus-ends of growing microtubules (MT). EB1 
is the prototypic member of MT plus-end tracking 
proteins (+TIPs), which controls MT dynamics 
and links MTs to several cellular structures such 
as kinetochores and cell cortex [1–3]. EB1 directly 
interacts with many other +TIPs and is therefore 
central to the assembly of +TIPs complexes at MT 
plus-ends. With its binding partners, EB1 participates 
in MT-mediated cell functions, such as cell division, 
migration and morphogenesis. MT constitute a 
longstanding, important and effective target for anti-
cancer drugs so-called Microtubule-Targeting Agents 
(MTA). MTA, including Vinca-alkaloids, taxanes and 
epothilones, are known to alter MT dynamic instability 
that is defined by growth to shrinkage transitions 
(catastrophes) and reverse transitions (rescues). 
However, the involvement of the proteins regulating 
MT plus-end dynamics in tumorigenesis and in drug 
response is still poorly understood. This question is very 
relevant in glioblastoma (GBM) cells, which motility is 
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a microtubule-dependent and actin polymer-independent 
process [4]. We previously demonstrated that the anti-
migratory effects of epothilone B on GBM cells occurred 
through an EB1-dependent mechanism and through 
MT catastrophe induction [5]. Such mechanism has 
also been described in GBM and endothelial cells with 
vinflunine (VFL) from the Vinca-alkaloid family [6]. 
A recent in vitro study with purified tubulin suggests 
that EB proteins sensitize MT to the action of MTA, by 
promoting MT catastrophes [7].
EB1 overexpression and its bad prognostic value 
have been described in several cancers, including breast 
cancer [8], esophageal squamous cell carcinoma [9], 
gastric adenocarcinoma [10], colorectal cancer [11] and 
hepatocellular carcinoma [12, 13].
GBM, the most common and malignant form of 
gliomas, is characterized by highly aggressive growth, 
and its invasive behavior that accounts for the poor 
overall survival (OS) of patients [14]. Current standard 
therapy following maximal safe removal consists of 
concomitant radio-chemotherapy with temozolomide 
(TMZ), an alkylating agent. Such regimen confers 
a median survival period of only 14.6 months 
and new therapeutic options are warranted [14]. 
Vinca-alkaloids are currently used in brain tumor 
treatment, more particularly vincristine (VCR), in 
combination with the alkylating agents procarbazine 
and lomustine for anaplastic oligodendrogliomas and 
oligoastrocytomas [15].
Here, we investigated the role of EB1 in GBM tumor 
progression and its potential predictive role for response 
to chemotherapy. We show that EB1 expression level has 
a prognostic value in GBM, and that Vinca-chemotherapy 
could improve the treatment of GBM patients with EB1-
overexpressing tumor.
RESULTS
EB1 overexpression correlates with poor overall 
survival and progression-free survival in patients 
with GBM
EB1 expression was examined in human GBM tissue 
specimens coming from 109 GBM patient cohort (Table 1). 
Immunohistochemical analysis was performed using clone 
5 anti-EB1 antibody (BD Bioscience) and isotype Ig as 
negative control. The EB1 expression appeared in the form 
of a cytoplasmic staining pattern (Fig. 1A). Scores were 
assigned as described in material and methods. EB1 staining 
and scores were validated by using another antibody against 
EB1 (clone H-70, Santa-Cruz Biotechnology) (not shown). 
Analysis of GBM tissue specimens revealed that out of the 
109 tissues specimens examined, 22 were scored 0 (21%), 
28 were scored 1+ (27%), 38 were scored 2+ (36%) and 
17 were scored 3+ (16%). In univariate analysis, a higher 
EB1 expression was correlated to poor OS (p < 0.001) and 
poor PFS (p < 0.001) (Fig. 1B, C). Median OS and PFS 
for each EB1 scoring are shown in Supplementary table 1. 
By multivariate analysis adjusted by KPs and gender 
(Table 2), EB1 expression remained significant both for 
OS (p < 0.001, Hazard Ratio: 1.583) and PFS (p = 0.001, 
Hazard Ratio: 1.458).
When tested on lower grades of glioma, EB1 was 
not detectable or weakly expressed. Indeed, only 6.0% 
(2/33) pilocytic astrocytoma samples were positively 
stained (score 1+), and all anaplastic astrocytoma samples 
tested (0/40) were negative (score 0) (not shown).
Interestingly, the other proteins of EB1 family, EB2 
and EB3, were expressed independently to EB1 scores in 
the 42 GBM tissue specimens analyzed (Supplementary 
Figure 1).
Table 1: Main clinical characteristics of 109 GBM patients cohort
Characteristics N %
Median age, years (range) 62.1 (21.1–79.7)
Male / Female 65/44 59.6/40.4
Median Karnofsky performance status (range) 70 (30–90)
Extent of surgery
- Complete resection 82
- Partial resection 27 24.8
Radiotherapy 84 77.1
Median OS, months (range) 13.2 (1.5–141.4)
Median PFS, months (range) 7.9 (0.9–132.4)
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Figure 1: Prognostic relevance of EB1 expression in glioblastoma. (A) Immunohistochemical staining of paraffin sections of 
glioblastoma tissue showing EB1 expression ranged from low to high: (a and b) score 0; (c and d) score 1+; (e and f) score 2+; and (g and h) 
score 3+. Arrows on magnified images show the cytoplasmic localization of EB1 in glioma cells (b, d, f, h). Bar = 50 μm. Kaplan–Meier 
overall survival (B) and progression-free survival (C) curves of 109 primary patients with different EB1 expression in glioblastoma tissue 
(score 0 to 3+).
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EB1 expression correlates with GBM cell 
migration and proliferation
In order to analyze the influence of EB1 expression 
in GBM tumor progression we generated six U87 stable 
clones deficient for EB1 (U87 sh4, sh11 and sh12) or 
overexpressing it (U87 P11, P15 and P16). Control clones 
U87 sh0 and P0 were generated with respective empty 
control vectors. EB1 expression level (ratio to GAPDH 
relative to U87-MG wt) in U87 sh4, sh11 and sh12 was 
around 2-fold lower than that in U87 sh0 control or U87-
MG wt cells. Conversely, in overexpressing-EB1 clones 
U87 P16, P11 and P15, the EB1/GAPDH ratio relative 
to U87-MG wt was respectively 3.6, 7.4 and 14.2 fold 
higher than in U87 P0 control or U87-MG wt cells 
(Fig. 2A). Modulations of EB1 expression in clones had 
no effect on the protein level of other EB family members 
or on the level of tubulin (Supplementary Fig. 1). EB1 
expression was confirmed in several GBM cell lines 
(U251-MG, U118-MG, U138-MG and GL15) and also 
in GBM stem-like cells isolated from 2 GBM patients 
(GBM6 and GBM9) [16] (Fig. 2B). Interestingly, EB1 
expression level was almost 17-fold higher in GBM6 
that is highly tumorigenic, as compared with GBM9 [17]. 
Finally, EB1 was not detected in human normal astrocytes 
(Supplementary Figure 2). Typical comet-like staining 
of EB1 was observed in U87 sh0 and P0 control cells 
(Fig. 2C). EB1 was barely visible in EB1 down-regulated 
clones as shown in U87 sh11, and stained in the entire 
length of MT in EB1 overexpressing clones without any 
MT bundling as illustrated with U87 P11.
Implication of EB1 expression level in GBM 
cell migration was assessed by using a transwell assay 
(Fig. 3A, B). The knockdown of EB1 expression 
significantly decreased cell migration (−22.5 ± 2.8%, 
−33.2 ± 1.4% and −47.3 ± 2.4% for U87 sh11, sh4 and 
sh12, respectively), whereas overexpression of EB1 
increased it (+41.6 ± 5.6% and +118.3 ± 6.2% for U87 
P11 and P15, respectively). The level of EB1 expression 
in U87-MG clones was significantly correlated with 
their migrating potential (linear regression, R² = 0.9496, 
p < 0.005) (Fig. 3C). Furthermore, introduction of siRNA 
against EB1 in EB1-overexpressing clones rescued the 
normal phenotype. Indeed, EB1 siRNA strongly reduced 
EB1 expression of U87 P11, 72 hours post transfection 
(Fig. 3D). EB1 silencing significantly decreased U87 
P11 cell migration, which returned to U87 P0 basal level 
(percentage of migrating U87 P11 cells was reduced by 
35.1 ± 4.4%) (Fig. 3E). Moreover, migration of astrocytes, 
with undetectable level of EB1, was significantly 
lower than U87-MG and U251-MG glioblastoma 
cells (−76.4 ± 4.5% versus U87-MG cells, p < 0.001) 
(Supplementary Figure 2C and D).
In addition, the involvement of EB1 in the 
migration of the two stem-like cells was investigated. 
We confirmed the strong migrating potential for 
GBM6 which was significantly higher than for GBM9 
(194.5 ± 4.0% in GBM6 vs 100% for GBM9) (Fig. 3G) 
that has been previously described by using the wound-
healing assay [16]. Moreover, EB1 down-regulation in 
GBM6 significantly abrogated migration by 52.9 ± 1.5% 
(Fig. 3F, G). Altogether, our data show that EB1 
overexpression leads to a pro-migratory phenotype in 
U87-MG cells as well as in GBM stem-like cells.
We next investigated the effect of EB1 expression 
on U87 cell proliferation using the BrdU staining assay. 
As shown in Fig. 4A, shRNA-mediated knockdown 
of EB1 expression slightly inhibited cell proliferation 
(−12.3 ± 0.9%, p < 0.05 and −23.5 ± 3.7%, p < 0.05 
for U87 sh11 and sh12, respectively). Conversely, EB1 
overexpression significantly promoted cell proliferation 
(+28.3 ± 2.1%, +55.7 ± 11.3% and +104.1 ± 8.2% 
for U87 P16, P11 and P15, respectively) (Fig. 4B). 
Together, these data revealed a positive and statistically 
significant correlation between the level of expression of 
EB1 in U87-MG cells and their proliferation rate (linear 
regression, R² = 0.9680, p < 0.001) (Fig. 4E), suggesting 
that EB1 is involved in U87 cell proliferation. The 
EB1 expression-dependent effect on proliferation was 
confirmed on cell growth by using the sulforhodamine B 
staining assay (Fig. 4C and D). Indeed, in the 3 shRNA 
clones with 2-fold lower EB1 expression, the doubling 
Table 2: Univariate and multivariate analysis of PFS and OS
Univariate Multivariate
Factors OS PFS OS Hazard Ratio PFS Hazard Ratio
Age 0.172 0.402
Extend of surgery 0.394 0.949
KPS 0.05 0.238 0.028 1.65 (1.056–2.578) 0.217
Gender 0.037 0.028 0.378 0.227
EB1 expression <0.001 <0.001 <0.001 1.583 (1.280–1.959) 0.001 1.458 (1.179–1.804)
KPS: Karnofsky Performans Status
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Figure 2: Modulation of EB1 expression in U87-MG cells. Western blot analysis of EB1 levels in shRNA EB1 clones (U87 sh4, 
sh11 and sh12), EB1 overexpressing clones (U87 P11, P15 and P16) or control clones (U87-MG wt, sh0 and P0) (A), and in GBM cell 
lines (U87-MG wt, U251-MG, U118-MG, U138-MG and GL15) or stem-like cells (GBM6 and GBM9) (B). Ratios EB1/GAPDH, relative 
to U87-MG wt, from at least three independent experiments are presented under the blots. (C) Immunofluorescence staining of tubulin 
(green) and EB1 (red) in U87 sh0, sh11, P0 and P11 clones. Bar = 10 μm. Magnified images show modifications of EB1 distribution on MT. 
Bar = 2 μm.
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time was increased by around 12 % and cell number was 
significantly decreased by around 15% at 96 hours. In 
contrast, EB1 overexpression decreased the doubling time 
in a EB1-dependent manner (−1%, −16.6% and −25.9% 
for U87 P16, P11 and P15, respectively) and significantly 
promoted cell growth (+6.4 ± 2.5%, +21.6 ± 3.0% and 
+39.6 ± 1.7% for U87 P16, P11 and P15, respectively) 
(Fig. 4D). These data were confirmed using a trypan 
blue dye exclusion assay (data not shown). Moreover, 
down-regulation of EB1 significantly decreased viability 
of U87 P11 cells by 12.5 ± 3.3%, thus rescuing partially 
the normal U87 P0 phenotype (Fig. 4F). Proliferation of 
astrocytes, that display undetectable staining of EB1, was 
also significantly lower than U87-MG and U251-MG 
glioblastoma cells (−59.61 ± 8.6% versus U87-MG cells 
at 96 hours, p < 0.001) (Supplementary Figure 2). Our 
results show that besides cell migration, EB1 expression 
level affects GBM cell proliferation.
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Figure 3: EB1 overexpression increases cell migration. (A) Representative images of migratory EB1-down-regulating 
and -overexpressing U87-MG clones using the transwell migration assay (crystal violet staining, magnification of 100×). (B) Quantification 
of migratory cells from EB1-down-regulating and -overexpressing U87-MG clones, as determined by counting the cell number under the 
microscope with a magnification of 100×, in the transwell migration assay. (C) Correlation analysis between cell migration expressed 
as percentage of control clones and levels of EB1 expression in the different U87-MG clones expressed as relative ratios EB1/GAPDH 
expression.
(Continued )
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EB1 overexpression increases tumor growth in 
an orthotopic mouse model of GBM
To confirm in vivo the effect of EB1 on GBM tumor 
progression, control U87 P0 or EB1 overexpressing 
U87 P11 clones were transplanted by stereotaxy in the 
striatum of nude mice. At post transplant days 14, 21 
or 28, animals were euthanized and serial coronal brain 
sections were stained with HE, then the size of the tumor 
was calculated by morphometry by using all the sections. 
Relative to control tumors, those overexpressing EB1 
were significantly more extended and the volume was 
increased at post transplant day 14 by 682.2 ± 316.1%, 
day 21 by 281.7 ± 32.9% and day 28 by 113.3 ± 17.2% 
(Fig. 5A, B). Ki-67 staining confirm that EB1 
overexpression increased proliferation rate of U87 P11 
tumors (+56.5 ± 8.2 % versus U87 P0 tumors, p < 0.05) 
(Supplementary Figure 3). The clinical condition of the 
mice was monitored daily. Weight loss was more rapid 
for mice bearing overexpressing EB1 tumors (Fig. 5C). 
Consequently, survival for these animals was strongly 
and significantly reduced (30.5 days for U87 P11 bearing 
mice vs 46 days for controls, p < 0.001) (Fig. 5D). Our 
previous work showing that GBM6 which overexpress 
EB1 gave rise to huge tumors when injected into brain, 
strengthens the current study [17].
Conversely, when mice were grafted with EB1 
down-regulated U87 sh12 clone, size of tumors was 
significantly reduced at post transplant days 14, 21 and 
28 (−98.0 ± 1.4% at day 14, −86.8 ± 6.3% at day 21 and 
−62.3 ± 14.9% at day 28, as compared with control U87 
sh0 bearing mice) (Fig. 5E, F). Weight loss was delayed 
and survival was significantly higher (survival gain of 
6.5 days, p < 0.005) (Fig. 5G, H).
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Figure 3 (Continued ): (D) Analysis of EB1 level expression by Western blot of U87 P11 cells treated with EB1 siRNA. U87 P11 
cells were incubated or not (U87 P11) with EB1-specific siRNA (U87 P11 siEB1) and siRNA control (U87 P11 si0). (E) Quantification 
of migratory U87 P11 cells treated or not (U87 P11) with EB1-specific siRNA (U87 P11 siEB1) or siRNA control (U87 P11 si0), in the 
transwell migration assay. (F) EB1 level expression of GBM6 treated with EB1 siRNA. GBM6 were incubated or not (GBM6 wt) with 
EB1-specific siRNA (GBM6 siEB1) and siRNA control (GBM6 si0). (G) Quantification of migratory GBM6 treated or not (GBM6 wt) 
with EB1-specific siRNA (GBM6 siEB1) or siRNA control (GBM6 si0), in the transwell migration assay. At least three independent 
experiments were performed for each condition. Bar ± SEM. (*) indicates significant differences from control: *p < 0.05; **p < 0.005; 
***p < 0.001, n.s.: non significant.
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Figure 4: EB1 overexpression increases cell proliferation. BrdU proliferation assay of down-regulating (A) or overexpressing 
(B) −EB1 clones in comparison with control U87 sh0 and P0 cells. Cell growth curves of down-regulating (C) or overexpressing 
(D) −EB1 clones in comparison with control U87 sh0 and P0 cells. (E) Correlation analysis between cell proliferation expressed as 
percentage of control clones and levels of EB1 expression in the different U87-MG clones expressed as relative ratios EB1/GAPDH 
expression. (F) Sulforhodamine B cell density assay at 72 hours of U87 P11 cells treated or not (U87 P11) with EB1-specific siRNA (U87 
P11 siEB1) or siRNA control (U87 P11 si0). At each time, analyses were performed in sixplicates. At least three independent experiments 
were performed for each condition. Bar ± SEM. (*) indicates significant differences from control: *p < 0.05; **p < 0.005; ***p < 0.001, 
n.s.: non significant.
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Response to Vinca-alkaloid treatment is 
enhanced in animals with EB1 overexpressing 
GBM cells orthotopically xenografted
To investigate in vivo the influence of EB1 
overexpression on drug response, VCR, a MTA used in 
the treatment of gliomas, and VFL, a new member of the 
Vinca-alkaloid family were tested. Control U87 P0 or 
EB1 overexpressing U87 P11 cells were transplanted by 
stereotaxy to the striatum of nude mice and animals were 
treated or not with VCR or VFL.
A significant survival benefit confirmed by mice 
weight analysis was observed when EB1 overexpressing 
U87 P11 bearing mice were treated with a Vinca-alkaloid, 
whatever the drug (Figure 6). The higher survival gain 
(13 days, p < 0.001) was obtained with VCR. Indeed, 
median survival was 39 days and 26 days for U87 P11 
bearing mice treated with VCR and vehicle, respectively 
(Fig. 6D). Survival gain was only 5 days in control 
U87 P0 bearing mice treated in the same conditions 
(median survival of 46 and 41 days after VCR and 
vehicle treatment, respectively) (Fig. 6B). Tumor volume 
measurements confirm these data. VCR strongly reduced 
tumor volumes in U87 P11 bearing mice (−90.5 ± 3.0% 
vs vehicle, p < 0.005) as compared with U87 P0 bearing 
mice (−62.2 ± 11.2% vs vehicle, p < 0.05) (Supplementary 
Figure 4). Proliferation rate was significantly reduced in 
U87 P11 cells but not in U87 P0 cells after VCR treatment, 
as shown by Ki-67 staining (−46.2 ± 7.0% vs vehicle, 
p < 0.005, at day 21) (Supplementary Figure 3).
A significant survival benefit (9 days, p < 0.005) 
was also obtained with VFL. Indeed, median survival of 
EB1 overexpressing U87 P11 bearing mice was 35 days 
and 26 days, after VFL and vehicle treatment, respectively 
(Fig. 6D). In contrast, survival of control U87 P0 bearing 
mice was not improved after VFL treatment (median 
survival of 45 and 41 days, after VFL and vehicle 
treatment, respectively) (Fig. 6B).
In contrast to VCR and VFL, which display an 
enhanced survival gain (+55 and 60% respectively) in 
EB1 overexpressing U87 P11 bearing mice, temozolomide 
(TMZ), the reference drug in GBM, induced a better 
survival gain in low EB1expressing U87 P0 bearing mice 
(48 days and 24 days, in U87 P0 and U87P11, respectively 
(Supplementary Figure 5). Taken together, our results 
show that EB1 expression, despite its bad prognostic 
value level, may be considered as a predictive marker for 
Vinca-alkaloid response in mice models.
EB1 overexpression sensitizes GBM cells to 
Vinca-alkaloid antimigratory and  
cytotoxic effects
For deciphering how EB1 overexpression influences 
GBM cell response to Vinca-alkaloid treatment, we 
assessed the effect of EB1 expression on the anti-
migratory properties of both VFL and VCR. VFL inhibited 
U87 P0 and U87 P15 cell migration in a dose-dependent 
manner (Fig. 7A, C). Interestingly, inhibition was more 
pronounced in EB1 overexpressing U87 P15 clone. 
Indeed, 6 nM VFL failed to alter control cell migration 
whereas it inhibited U87 P15 cell migration (−57 ± 1.9%). 
This result has been confirmed with EB1 overexpressing 
U87 P11 clone (−39.4 ± 9.5%) (Fig. 7B, D). Moreover, 
at higher concentrations of VFL, inhibition of migration 
was more efficient in U87 P15 than in U87 P0 cells 
(Fig. 7A, C). These data demonstrate that EB1 expression 
level in GBM cells modulates VFL anti-migratory effect. 
EB1 overexpression also sensitized cells to VCR in U87 
P15 cells (−56.7 ± 2.1% vs −43.3 ± 6.0% for U87 P15 and 
U87 P0, respectively) (Fig. 7A, C) and in U87 P11 cells 
(−60.0 ± 1.9 % vs −41.9 ± 4.1 % for U87 P11 and U87 P0, 
respectively) (Fig. 7B, D). In contrast, we did not detect 
any significant difference of the anti-migratory effect of 
TMZ according to EB1 expression (Fig. 7B, D).
Further, we conducted a dose response cytotoxic 
activity assay of VFL on the two overexpressing-EB1 U87-
MG clones after 72 hours of treatment (Fig. 7E). The drug 
concentration required to reduce viability by 50% (EC50) 
was 10.6 ± 1.8 nM for U87 P11 and 7.0 ± 1.8 nM for U87 
P15 in comparison with 38.0 ± 1.5 nM for control U87 P0. 
Moreover, the concentration of VCR required to reduce 
viability by 50% (EC50) was 0.60 ± 0.22 nM for U87 
P11 and 0.61 ± 0.10 nM for U87 P15 in comparison with 
1.42 ± 0.05 nM for control U87 P0 (Fig. 7F). Conversely, 
we did not detect any difference of cytotoxicity after 
TMZ treatment in the same experimental conditions 
(EC50 = 500.3 ± 162.4 μM and 578.6 ± 152.1 μM for 
U87 P0 and U87 P11 cells respectively) (Fig. 7G). 
These data obtained in vitro supports the results from the 
in vivo study, and demonstrate that EB1 overexpression 
specifically sensitizes to Vinca-alkaloids anti-migratory 
and cytotoxic effects in GBM cells.
Vinca-alkaloids antagonize the alteration of MT 
dynamics induced by EB1 overexpression
In order to decipher the cellular mechanism of 
Vinca-alkaloid sensitization, we analyzed the effects 
of VCR on MT dynamic instability from EB3-GFP 
comet data in control U87-MG cells and U87 EB1 
overexpressing cells (Table 3). First, our results clearly 
show that EB1 overexpression increased the MT growth 
rate (+59.6%, p < 0.01), and strongly decreased the 
distance-based catastrophe frequency (−41.3 %, p < 0.01). 
Analysis of microtubule dynamics from CLIP-170-GFP 
comet data confirmed the decrease in the distance-based 
catastrophe frequency in U87 P15 versus U87 P0 cells 
(−20%, p < 0,05). In U87 P0 cells, VCR did not alter the 
growth rate and catastrophe frequency, excepted at the 
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higher concentration (1.6 nM). Indeed, this cytotoxic and 
anti-migratory concentration slightly increased the MT 
catastrophe frequency (+23.2%, p < 0.05, for 1.6 nM). In 
contrast, in U87 P11, VCR strongly increased the distance 
based-catastrophe frequency at all the concentrations 
(+52.3%, p < 0.05 at 0.8 nM, + 64.4%, p <0.01 at 
1.2 nM and +69.2%, p < 0.01, at 1.6 nM) and statistically 
decreased the MT growth rate (−31.1 %, p < 0.05 at 
1.2 nM and −27.9% , p < 0.05 at 1.6 nM). These results 
suggest that VCR antagonize the alterations of MT 
dynamics induced by EB1 overexpression. Samples videos 
are presented in Supplemental movies 1 to 4.
DISCUSSION
In this study, we identified EB1 as a potential 
prognostic marker in GBM patients and a predictive 
factor of response to Vinca-alkaloid treatment. Moreover, 
the prognostic impact on OS and PFS was shown to be 
independent of other known prognostic factors including 
age, functional status, and surgery. Further studies for 
testing EB1 in addition to other biomarkers such as 
MGMT status and IDH1 mutation are warranted in 
patients with GBM and other high grade gliomas to 
confirm EB1 prognostic role [18–22].
By modulating EB1 expression in U87-MG cells, 
we have shown that EB1 promotes GBM cell proliferation 
and migration, thus confirming the well-described role 
of EB1 in the mechanism of cell migration [23–25] and 
cell division [8, 9, 26, 27]. Furthermore, we show for 
the first time that EB1 promotes GBM tumor growth in 
nude mice. Analysis of the GBM-derived stem-like cells 
GBM6 and GBM9 strengthen these observations. GBM6 
that strongly overexpressed EB1 in contrast to GBM9, 
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Figure 7: EB1 overexpression sensitizes glioblastoma cells to Vinca-alkaloid anti-migratory and cytotoxic 
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showed an EB1-dependent and strong migratory potential, 
and a higher tumorigenicity with a more infiltrative 
pattern in vivo [17]. In addition, gene expression profiles 
evidenced a distinctive gene expression signature 
for GBM6 and GBM9, characterized by a specific 
overexpression of genes involved in cell migration and 
adhesion for GBM6. However, when this analysis was 
performed, EB proteins were not selected for migration 
signature. Based on their original brain location and their 
distinctive molecular signature, GBM6 and GBM9 have 
been classified as mesenchymal and proneural GBM 
subtypes respectively [17]. Since EB1 overexpression 
seems to be specific to GBM6, EB1 expression profile 
should be included to the other known distinctive genes 
characterizing mesenchymal GBM, and may help to define 
new subtypes.
Interestingly, our study allows us to add EB1 
among the proteins regulating the MT cytoskeleton that 
are overexpressed in GBM such as spastin, class III 
β-tubulin and γ-tubulin [28, 29]. Further work is needed 
to decipher the interactions between these proteins. For 
example, γ-tubulin complexes and EB1 have been shown 
to produce apparent antagonistic effect on MT dynamics 
and spindle positioning in HeLa Cells [30]. However, such 
interaction may be interpreted only after a deep knowledge 
of EB1 effect on MT dynamic instability, taking into 
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Figure 7 (Continued ): Dose response curves of the cytotoxicity of VFL (E), VCR (F), or TMZ (G) in overexpressing-EB1 U87 P11 
and/or U87 P15 clones, in comparison with control U87 P0 cells. At least three independent experiments were performed.
Table 3: Microtubule dynamic instability parameters from EB3-GFP or CLIP-170-GFP  
comet tracks
Growth Rate 
(μm/min)
Growth Length 
(μm)
Growth Time 
(min)
Catastrophe 
Frequency (μm-1)
Catastrophe 
Frequency (min-1)
U87 P0-EB3-GFP 
Control 7.45 ± 0.75 1.82 ± 0.16 0.25 ± 0.01 0.55 ± 0.05 3.93 ± 0.11
 0.8 nM VCR 7.82 ± 0.51 1.86 ± 0.13 0.24 ± 0.005 0.54 ± 0.04 4.09 ± 0.08
 1.2 nM VCR 7.36 ± 0.13 1.66 ± 0.02 0.23 ± 0.006 0.6 ± 0.01 4.26 ± 0.11
 1.6 nM VCR 6.53 ± 0.25 1.48 ± 0.06 0.24 ± 0.004 0.68 ± 0.03* 4.23 ± 0.06
U87 P11-EB3 –GFP 
Control 11.89 ± 1.31
## 3.11 ± 0.34## 0.26 ± 0.01 0.32 ± 0.04## 3.81 ± 0.16
 0.8 nM VCR 10.24 ± 0.61 2.04 ± 0.20* 0.21 ± 0.014* 0.49 ± 0.05* 4.84 ± 0.32*
 1.2 nM VCR 8.19 ± 0.67* 1.89 ± 0.11** 0.24 ± 0.013* 0.53 ± 0.03** 4.11 ± 0.22*
 1.6 nM VCR 8.58 ± 0.23* 1.84 ± 0.03** 0.23 ± 0.002* 0.54 ± 0.01** 4.41 ± 0.04*
U87 P0-CLIP170-
GFP 11.0 3± 0.92 2.41 ± 0.12 0.22 ± 0.01 0.41 ± 0.02 4.55 ± 0.27
U87 P15-CLIP170-
GFP 12.32 ± 1.02 3.03 ± 0.23
# 0.24 ± 0.01 0.33 ± 0.03# 4.17 ± 0.15
#p < 0.05; ##p < 0.01 (vs P0); *p < 0.05; **p < 0.01 (vs Control)
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account several factors such as EB1 expression level and 
post translational modifications like phosphorylation and 
detyrosination [31–33].
Recent publications indicate that EB1 may play 
a role in tumorigenesis suggesting that beyond its 
prognostic value, EB1 could be considered as a potential 
oncogene. EB1 induces cell proliferation through the 
activation of beta-catenin/Tcell factor pathway [9, 21], 
and the activation of aurora-B [34], a kinase essential 
for mitosis in breast cancer for which EB1 negatively 
impacts survival [8]. Interestingly, aurora-B expression 
correlates with GBM aggressive behavior [27]. It has 
also been shown that abnormal detyrosination of the 
tubulin C-terminal EEY sequence promotes tumor cell 
growth, which represents a significant marker of tumor 
aggressiveness in breast cancer [35]. We recently found 
that EB1, which shares the same C-terminal sequence as 
tubulin [36, 37], undergoes a C-terminal detyrosination 
process in GBM cells, which also may account for 
enhanced tumor progression [6]. Furthermore, tubulin 
detyrosination as well as EB1 detyrosination, are known 
to impair accumulation of CAP-Gly proteins at growing 
MT plus-end, thus altering MT dynamics and related cell 
functions [37, 38].
Finally we demonstrated that EB1 overexpression 
sensitizes GBM cells to Vinca-alkaloids by enhancing 
anti-migratory and cytotoxic effects. However, EB1 
overexpression in GBM cells did not improve the response 
to TMZ. These results suggest that the mechanism of 
sensitization by EB1 is MT-dependent. Indeed, we 
demonstrated that Vinca-alkaloids alter so potently MT 
dynamics in EB1 overexpression that they completely 
reverse the phenotype due to EB1 overexpression. Our 
results are consistent with a recent publication describing 
in vitro a mechanism of cooperation between EBs 
and MTA [7]. Indeed, in the presence of EB proteins, 
MT growth rates were inhibited and MT catastrophes 
were increased at concentrations of drugs that did not 
affect MT dynamics in the absence of EB. The authors 
suggested that catastrophes were MT age-dependent, and 
that MT depolymerizing drugs accelerate aging in an EB-
dependent manner. Moreover, we previously reported 
in U87-MG cells that anti-migratory effect of VFL was 
associated with the inhibition of EB1 accumulation at MT 
plus-end and with the decrease of C-ter detyrosinated form 
of EB1 [6]. This shift in post-translational modification of 
EB1 may participate to Vinca-alkaloid antitumor activity, 
if one considers that detyrosinated EB1 promotes tumor 
progression as described with detyrosinated tubulin [35]. 
It is also conceivable that increased cell proliferation may 
sensitize the cells to the action of cell cycle-dependent 
anticancer drugs.
Altogether, our data open new avenues of research 
on the role of EB1 in GBM tumor progression that has 
limited therapeutic options. Subgroups of glioma patients 
with EB1 overexpressing tumor should be identified. 
Furthermore, MT targeting drug activity should be 
evaluated in regard to EB1 status in cancer patients.
MATERIALS AND METHODS
Drugs
Vinflunine (Pierre Fabre France) and vincristine 
(Sigma-Aldrich) were solubilized in sterile distilled water 
or in a saline solution. Temozolomide was extracted from 
5 mg Temodal® capsules in dimethyl sulfoxide (DMSO).
Patients and tissue samples
We analyzed 109 patients with GBM referred 
to our institution. Seventy-two of them were included 
in tissue microarrays (TMA) that were constructed 
from formalin-embedded tumor material. Brain tumor 
samples were classified according to WHO CNS tumor 
classification [39] and their main clinical features are 
reported in Table 1. Areas of viable and representative 
tumor following review of all blocks were marked by two 
pathologists prior to inclusion into the TMA (3 × 0.6 mm 
cores for each tumor) [40, 41]. Consensual prognostic 
factor such as age, functional status analyzed by 
Karnovsky Performance Score (KPS), and surgery were 
collected. Patients were routinely follow-up with brain 
MRI every two months and assessment of progression 
was performed according to MacDonald criteria’s [42]. 
TMA containing tissue from 33 patients with pilocytic 
astrocytoma (WHO grade 1) and 40 patients with anaplasic 
astrocytoma (WHO grade 3) were also analyzed. The 
study was undertaken after informed consent from each 
patient or their relatives, in accordance with institutional 
board guidelines.
EB1 immunohistochemistry was carried out, using 
an anti-EB1 primary antibody (clone 5, BD Biosciences) 
[8, 9], and avidin–biotin–peroxidase method [43]. Isotype 
control antibody (BD Biosciences) was used at the same 
concentration as primary antibody. For confirmation, 
a second anti-EB1 primary antibody was also used 
(clone H-70, Santa-Cruz Biotechnology) [13]. EB2 and 
EB3 immunohistochemistry was performed using an 
anti-EB2 primary antibody (Abcam, ab56753), and 
an anti-EB3 primary antibody (Abcam, ab157217). 
Positive cells were scored based on cytoplasm staining 
of EB1. Only tumor cell staining was taken into account, 
excluding hypertrophic endothelial cells in tumor blood 
vessels. The number of positive immunostained cells out 
of the total number of tumor cells (˃ 1,000) in 20 non-
overlapping high power fields (30,000 μm², objective 
40X) per clinical sample was analyzed. EB1 expression 
was classified semi-quantitatively according to the 
visual scoring as 0 (undetectable staining in tumor cells), 
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1+ (<10% of tumor cell staining), 2+ (10%–50% of tumor 
cell staining, or 3+ (>50% of tumor cell staining). Manual 
cell counting of labeled tumor cells was performed by 2 
pathologists independently, without knowledge of the patient 
clinical status. The coefficient of variation of interobserver 
reproductibility was 9.68% for EB1 expression scoring, with 
no significant difference between the two observers (paired 
t-test, p = 0.88).
Cell culture and transfection
Human glioblastoma U87-MG cell line was ordered 
from ATCC (number HTB14). Human glioblastoma 
U118-MG, U251-MG, U138-MG and GL15 cells were 
kindly provided by D. Figarella-Branger (Pathology 
and Neuropathology Unit and Tumour Bank). U87-MG, 
U251-MG, U118-MG, U138-MG and GL15 cells were 
grown in EMEM media with glucose and L-glutamine 
(Lonza, Levallois-Perret, France), containing 10% 
fetal calf serum (Lonza), 1% penicillin/streptomycin 
(Sigma-Aldrich, Saint-Quentin Fallavier, France). GBM 
stem-like cell lines GBM6 and GBM9 were isolated from 
GBM patients and grown as previously described [16]. 
Normal human astrocytes were purchased from Lonza 
and cultured in Astrocytes Basal Media supplemented with 
astrocyte growth medium SingleQuots (Lonza). All cell 
types were tested weekly for the presence of mycoplasma, 
using MycoalertTM Mycoplasma Detection Kit (Lonza).
ShRNA plasmid that specifically knocked out 
human EB1 (NM_012325) and negative shRNA control 
plasmid (Mission® non-target shRNA control vector) were 
obtained from Sigma-Aldrich. EB1 expression plasmid 
(16474) and negative control plasmid (16440) were 
obtained from Addgene. U87-MG cells were transfected 
with lipofectamineTM 2000 system (Invitrogen). For 
establishing stable clones, the shRNA-transfected cells 
and related control clones were selected in culture 
medium containing puromycin (Sigma-Aldrich) 24 hour 
post-transfection. EB1-overexpressing clones and related 
control clones were selected in 800 μg/ml G418. For EB1 
silencing by transient transfection, cells were transfected 
by lipofectamine 2000 system with siRNA for EB1 
(Hs_MAPRE1-5, Qiagen) and all STAR control (Qiagen). 
EB1 down-regulation was analyzed 48 hours or 72 hours 
later by western blotting.
Immunofluorescence and western blot analysis
Indirect immunofluorescence was performed as 
previously described [5] by using the anti-EB1 antibody 
and anti-mouse antibody Alexa 568 nm (Molecular 
Probes); and FITC-coupled anti-α-tubulin antibody (clone 
DM1A; Sigma-Aldrich). Cells were observed using 
a Leica DM-IRBE microscope, 100X magnification. 
All images were acquired using Metamoph software 
(Molecular Devices, Sunnyvale, CA) at identical 
acquisition settings, and were processed using Image 
J software. After cell lysis, 30 μg of total protein were 
loaded into a 12% SDS-PAGE gel. Anti-EB1 antibody, 
anti-α-tubulin and anti-mouse IgG-horseradish 
peroxidase (Jackson Immunoresearch) were used. 
Chemiluminescence detection kit (Millipore) was used for 
visualization of protein bands. Chemiluminescent signal 
was acquired on a G:BOX imaging system (Syngene, 
Cambridge, UK) and quantification was done with Image 
J software.
Analysis of cell proliferation
Cell proliferation was assessed using 
5-bromodeoxyuridine (BrdU) immunohistochemistry as 
previously described [44]. After 4-hour incubation with 
3 μg/mL BrdU (Sigma-Aldrich), cells were labelled with 
monoclonal anti-BrdU antibody (Sigma-Aldrich) followed 
by Alexa 568 nm anti-mouse antibody (Molecular Probes). 
Nuclei were stained with 4′6-diaminido-2-phenylindole 
(DAPI; Sigma-Aldrich). The stained cells were observed 
under microscope, 20X magnification. Minimums of 
200 cells were scored for BrdU incorporation. Cell growth 
analysis was performed using the sulforhodamine B assay 
as previously described [45]. For cytotoxicity assay, drugs 
were added to the medium 24 h after cell seeding. At least 
three independent experiments were performed for each 
condition.
Transwell migration assay
Cells (5 × 104 cells/well) were seeded on the upper 
side of transwell migration chamber (Becton Dickinson, 
Le Pont de Claix, France) and allow migrating for 5 hours 
as previously described [5]. Six fields per condition were 
imaged and transmigrated cells were counted. Results 
were expressed as percent of transmigrated cells compared 
with no treatment condition. At least three independent 
experiments were performed for each condition.
Animal studies
Intracerebral tumor transplantation
All experimental procedures and animal care were 
carried out in conformity with the guidelines of the French 
Government and approved by the Regional Committee 
for Ethics on Animal Experiments. Six to 8 weeks old 
female Swiss nude mice were obtained from Charles 
River Laboratories France (L’Arbresle, France). After 
animal anesthesia, 5 × 105 tumor cells were injected into 
the striatum of the mice, as previously described [46].
Experimental design
To evaluate consequences of the level of EB1 
expression in GBM progression, 4 groups were constituted: 
mice bearing U87 P0 (n = 17), U87 P11 (n = 17), U87 
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sh0 (n = 17) and U87 sh12 (n = 17). For analysis of 
EB1-overexpression on antitumor effects of drugs, groups 
of U87 P0 and U87 P11 bearing mice were constituted, and 
received VCR (n = 14), VFL (n = 14), TMZ (n = 14) or 
vehicle solutions (control groups) (n = 14).
Treatments
VFL (20 mg/kg/day) or VCR (0.8 mg/kg/day) 
treatments were administered intravenously at days 4, 
7, 11, 14, 18 and 21 after glioma implantation according 
to the treatment schedule previously described [47] and 
preliminary tolerance studies (not shown). VFL and VCR 
were dissolved at 2.5 mg/ml and 0.16 mg/ml respectively in 
0.9% NaCl. TMZ (5 mg/kg) was administered daily i.p. for 
four consecutive days, at day 5 after tumor cell implantation. 
TMZ was administered in a solution of 10% DMSO in 
0.9% saline. Vehicle solutions were given to control groups.
Animal observation
Animals were monitored each day for weight loss, 
ataxia, and periorbital hemorrhage [48]. For study of EB1-
overexpression consequences in glioma progression, three 
animals per group were sacrificed at post tumor transplant 
day 14, 21, and 28, and brains were removed and stored 
at -80°C.
Tumor volume evaluation
Frozen brains were serially sectioned using a 
Leica cryostat, and 20 μm sections were stained with 
Hematoxylin/Eosin (HE) for histomorphology and 
measures of the tumor volume. Images of HE-stained 
sections were captured with a Leica Z16APO macroscope 
using the Leica Application Suite 2.8.1 Software. The 
tumor area was manually outlined and measured using 
Image J software. Knowing the thickness and the number 
of sections, we calculated the total volume of each tumor. 
Tumor volumes were measured for three animals per group.
Assessment of tumor cell proliferation
Ki-67 immunostaining were performed on 
sections from paraffin embedded samples, with 
monoclonal Anti-Ki-67 antibody (clone MIB-1; Dako) 
and hematoxylin counter-staining. Three random 
representative fields within tumor areas were used for 
quantitation. Each Ki-67 positive cell was counted and 
normalized to the total number of cells in each field.
Analysis of microtubule dynamics from  
EB3-GFP and CLIP 170-GFP comet data
U87-MG cells (6 × 104 cells/well) were grown for 
24 hours on 8-well Labtek II chamber slides (Labtek, 
Thermo Scientific, Roskilde, Denmark) precoated 1 hour 
with fibronectin (10 μg/ml). U87-MG cells were then 
transfected with plasmid coding for green fluorescent 
protein EB3-GFP or CLIP 170 GFP using lipofectamineTM 
2000 system (Invitrogen). Before microscopy analysis, 
cells were incubated with various concentrations of VCR 
for 4 hours.
Time-lapse acquisitions for microtubule dynamic 
instability experiments were performed with a Leica 
DM-IRBE equipped with a 100X objective lens. Sixty 
images per cell were acquired at 2-s intervals using a 
digital camera (CCD camera Coolsnap FX; Princeton 
Instruments). EB3-GFP comets were detected using the 
plusTipTracker package [49]. The software package 
can be downloaded from http://lccb.hms.harvard.edu. 
Comet detection requires no user intervention, as the 
detection algorithm automatically estimates locally 
optimal thresholds. Tracking and inference of complete 
MT trajectories by plusTipTracker requires user-defined 
settings of several control parameters (Watershed-based 
detection: sigma 1 = 3; sigma 2 = 4 and K = 1; Tracking 
search radius range = 5–10 pixels, minimum subtrack 
length = 4 frames, maximum gap length = 12 frames, 
max shrinkage factor = 1.5, maximun angle forward = 30° 
and backward = 10°; fluctuation radius = 1.5 pixel ; Post 
processing frame rate = 2s; pixel size = 130 nm). Correct 
tracking was verified by visual inspection of several 
overlay movies. The parameter settings were kept identical 
for all movies. The plusTipTracker software package 
contains modules for the parameterization of trajectories 
characterizing MT dynamics within one movie and for the 
comparison of the dynamics between movies. Many of 
the metrics are redundant and thus cannot be considered 
for comparative analyses without further dimensionality 
reduction. To assess the consistency we chose 5 metrics 
for pair-wise statistical testing: mean growth speed, 
mean growth lifetime, mean growth length, time–based 
catastrophe frequency and distance-based catastrophe 
frequency. A t-test was performed for each of these 
metrics. For each experimental condition, 5 to 8 cells were 
analysed (400-1200 tracks per cell).
Statistical analysis
Data are presented as mean ± SEM. Cell counting, 
cellular viability data, tumor volumes were analyzed 
by Student’s t test. Overall survival (OS) was defined 
to be the time from GBM diagnosis to death from any 
cause, censored at the date of last contact. Progression-
Free Survival (PFS) was defined to be the time from 
GBM diagnosis to progression or death, censored at 
the date of last contact. PFS and OS were estimated by 
the Kaplan-Meier method. The log-rank test was used 
to estimate survival distributions. Prognostic factors 
with p < 0.15 in univariate analysis were explored in 
multivariate analysis. Cox proportional hazards models 
Oncotarget17www.impactjournals.com/oncotarget
were used for multivariate analyses and to estimate 
hazard ratios in regression models. Reported p-values 
are two-sided, and p < 0.05 was considered statistically 
significant. Asterisks indicate significant level vs control 
*p < 0.05; **p < 0.005; ***p < 0.001. Statistical analyses 
were performed with spss.version17® and GraphPad 5.0 
statistical software.
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